ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Jibacoa	6/3/2016 8:30:28 AM
	of 4474

After announcing that it will receive approximately $140 Ms from the sale to Incyte an exclusive license to develop and commercialize Iclusig in the European Union and 22 other countries, including Switzerland, Norway, Turkey, Israel and Russia, ARIA will have enough Csh to proceed with its other plans, including the P I/II of AP32788 for the treatment of patients with NSCLC with specific mutations in EGFR or HER2. The stock is among the ones moving well in PreMarket trading, it is up 4.38% at the $9.30 level with the resistances now to watch been its August Hs at the 9.53 to the 10.07 level.<g> elite.finviz.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next